Compare drug alternatives

Stiolto Respimat® Alternatives

Stiolto Respimat®(olodaterol / tiotropium)
Trelegy Ellipta ®(fluticasone furoate)
Prescription Only
Stiolto Respimat is a medication comprising a combination of olodaterol and tiotropium. Olodaterol acts as a long-acting bronchodilator, while tiotropium functions as an...
Prescription Only
TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta2-adrenergic agonist...
Dosage & Administration
Administration
Dosing
Latin Shorthand
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
Assistance Expiration
12/31/2024. Learn more.
12/31/2023. Learn more.
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
The most common adverse reactions (>3% incidence and more than an active control) were nasopharyngitis, cough, and back pain. . Learn more.
COPD: Most common adverse reactions (incidence ≥1%) are upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, headache, back pain, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis, oropharyngeal pain, cough, and dysphonia. (6.1) Asthma: Most common adverse reactions (incidence ≥2%) are pharyngitis/nasopharyngitis, upper respiratory tract infection/viral upper respiratory tract infection, bronchitis, respiratory tract infection/viral respiratory tract infection, sinusitis/acute sinusitis, urinary tract infection, rhinitis, influenza, headache, and back pain.. Learn more.
Mechanism of Actions (MoA)
Anticholinergics. Learn more.
Anticholinergics . Learn more.
Special Populations
8.1 Pregnancy Risk Summary

Insufficient data are available on the use of TRELEGY ELLIPTA or its individual components (fluticasone furoate, umeclidinium, and vilanterol) in pregnant women to determine a drug-associated risk. Animal studies showed no adverse effects on embryofetal development for these components at exposures approximately 4.5 to 200 times the maximum recommended daily inhalation doses in adults.

8.2 Lactation Risk Summary

No information is available on the presence of these components in human milk, their effects on the breastfed child, or milk production. Umeclidinium was detected in the plasma of offspring of lactating rats treated with umeclidinium, suggesting its presence in maternal milk.

8.4 Pediatric Use

TRELEGY ELLIPTA is not approved for use in pediatric patients, and its safety and efficacy in pediatric patients have not been established.

8.5 Geriatric Use

No dosage adjustment is necessary for geriatric patients, but greater sensitivity in some older individuals cannot be ruled out.

8.6 Hepatic Impairment

TRELEGY ELLIPTA has not been studied in subjects with hepatic impairment. Information on the individual components is provided.

8.7 Renal Impairment

TRELEGY ELLIPTA has not been studied in subjects with renal impairment. Information on the individual components is provided.